Several Data of Infection in COVID-19 Patients during March-June 2020 at the First University Clinic of Tbilisi State Medical University, Georgia

L. Ratiani, L. Gabunia, Sh. Khetsuriani, N. Gamkrelidze, E. Varazi

Abstract


The emergence of disease COVID-19 in China at the end of 2019 is a major public health issue. Public health and infection control measures are urgently required to limit the spread of this global viral infection.

160 patients were admitted to the First University Clinic of Tbilisi State Medical University (TSMU) during March-June 2020. We  retrospectively studied these cases according to gender and age of patients, lethal outcome rate, hospitalization days and  frequency of different comorbid diseases. Also, observations were carried out on patients taking angiotensin converting enzyme(ACE) inhibitors and angiotensin 1(AT1) receptor blockers due to heart failure or arterial hypertension. Among COVID-19 lethal outcome patients, frequency between female and male was not significantly different (44.4% vs. 55.6%). Frequency of infected patients was the most common in 30-59 of ages (45.3%). Average hospitalization days were 21. Mortality rate was 5.6%, mostly in age above 60 (88.8%). Among lethal outcome patients, 88.8% had comorbid diseases. Heart failure, acute kidney injury, sepsis, essential arterial hypertension III, mitral valve defect, nontoxic diffuse goiter and etc; were the most common underlying conditions. Covid-19 Convalescent patients with arterial hypertension (55%) which were not treated with angiotensin converting enzyme inhibitors and angiotensin 1 receptor blockers, required less hospitalization days, approximately 2-3 days (62 hours).


Keywords


COVID-19 infection, mortality rate, comorbid diseases, angiotensin converting enzyme inhibitors, angiotensin 1 receptor blockers.

Full Text:

PDF

References


Eurosurveillance Editorial Team. Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Eurosurveillance. 2020 Feb 6;25(5):200131e.

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. The Lancet. Respiratory Medicine. 2020 Apr;8(4):e21.

GÜNER HR, HASANOĞLU İ, AKTAŞ F. COVID-19: Prevention and control measures in community. Turkish Journal of medical sciences. 2020 Apr 21;50(SI-1):571-7).

Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments. Science 2020. https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments (Accessed on March 26, 2020)

Molina JM, Delaugerre C, Goff JL, et al. No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection. Medecine et Maladies Infectieuses 2020]

S Kannan 1, P Shaik Syed Ali, A Sheeza, K Hemalatha COVID-19 (Novel Coronavirus 2019) - Recent Trends Eur Rev Med Pharmacol Sci 2020 Feb;24(4):2006-2011).


Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 L. Ratiani, L. Gabunia, Sh. Khetsuriani, N. Gamkrelidze, E. Varazi

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.